Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Blood (2022) 140 (Supplement 1): 2002–2004.

https://doi.org/10.1182/blood-2022-159503

Published: 2022

Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Blood (2022) 140 (Supplement 1): 526–528.

https://doi.org/10.1182/blood-2022-162377

Published: 2022

Journal Articles

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 1367.

https://doi.org/10.1182/blood-2019-128044

Published: 2019

Journal Articles

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Maria del Mar Cuadrado, MBBS, Mark W. Lowdell, BSc, MSc, PhD FRCPath, Stuart Ings, Michael J. Watts, PhD, Richard Szydlo, PhD, Chloe Anthias, MD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath, Panagiotis Kottaridis, FRCPath,PhDMSc, Ben Carpenter, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath, Karl Peggs, MBBChir, Kirsty Thomson, PhD, Emma Morris, FRCPath, MA, MBBChir, PhD MRCP, Ronjon Chakraverty, BMBS, PhD

Blood (2018) 132 (Supplement 1): 204.

https://doi.org/10.1182/blood-2018-99-115054

Published: 2018

Journal Articles

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Blood (2018) 131 (8): 917–931.

https://doi.org/10.1182/blood-2017-09-807487

Published: 2018

Journal Articles

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Emma C Morris, MD PhD, Thomas Andrew Fox, MRCP, Siobhan Burns, MD PhD, Ben Carpenter, MD, Kirsty J Thomson, MD, David Lowe, MD PhD, Adele K. Fielding, MB BS, PhD FRCP, FRCPath, Karl S Peggs, MD, Panagiotis Kottaridis, FRCPath, PhD MSc, Victoria Grandage, FRCPath, MRCP, PhD, Shari Denovan, RN, Sarah Grace, RN, Julia Dahlstrom, RN, Sarita Workman, RN, Andrew Symes, RN, Stephen Mackinnon, MD, Ronjon Chakraverty, BMBS, PhD, Rachael Hough, MD BMBS, FRCP, FRCPath

Blood (2016) 128 (22): 4681.

https://doi.org/10.1182/blood.V128.22.4681.4681

Published: 2016

Journal Articles

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Panagiotis Kottaridis, MD, PhD, Maria Tsirogianni, MD, Janet North, BSc, MSc, Chloe Marden, PhD, Stephen Mackinnon, MD, Mark W Lowdell, PhD, FRCPath

Blood (2011) 118 (21): 946.

https://doi.org/10.1182/blood.V118.21.946.946

Published: 2011

Journal Articles

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

Karl S Peggs, Irfan Kayani, Kirsty Thomson, Emma Morris, MD, Panagiotis Kottaridis, Kirit M Ardeshna, MD, Adele Fielding, Rachael Hough, Anthony H Goldstone, MD, Ronjon Chakraverty, David C Linch, MD FMedSci, Stephen Mackinnon

Blood (2011) 118 (21): 2016.

https://doi.org/10.1182/blood.V118.21.2016.2016

Published: 2011

Journal Articles

A Cell Line SYRMO Derived From AML with EVI 1 Rearrangements Following Imatinib Mesylate Therapy for Chronic Myeloid Leukaemia

Panagiotis Kottaridis, Diana Brazma, Julie Howard-Reeves, Helen Mazzullo, Elisabeth P Nacheva, MD, PhD

Blood (2010) 116 (21): 4470.

https://doi.org/10.1182/blood.V116.21.4470.4470

Published: 2010

Journal Articles

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Blood (2010) 116 (16): 3080–3088.

https://doi.org/10.1182/blood-2010-05-286856

Published: 2010

Journal Articles

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation

Andrea Knight, Alejandro J. Madrigal, Sarah Grace, Janani Sivakumaran, Panagiotis Kottaridis, Stephen Mackinnon, Paul J. Travers, Mark W. Lowdell

Blood (2010) 116 (12): 2164–2172.

https://doi.org/10.1182/blood-2010-01-255166

Published: 2010

Journal Articles

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

Andrew J. Steele, Archibald G. Prentice, A. Victor Hoffbrand, Birunthini C. Yogashangary, Stephen M. Hart, Mark W. Lowdell, Edward R. Samuel, Janet M. North, Elisabeth P. Nacheva, Anastasios Chanalaris, Panagiotis Kottaridis, Kate Cwynarski, R. Gitendra Wickremasinghe

Blood (2009) 114 (6): 1217–1225.

https://doi.org/10.1182/blood-2008-11-190587

Published: 2009

Includes: Supplemental data

Journal Articles

The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation.

Julio Delgado, Nichola Cooper, Kirsty Thomson, Rafael Duarte, Panagiotis Kottaridis, Karl Peggs, Stephen Mackinnon

Blood (2004) 104 (11): 2257.

https://doi.org/10.1182/blood.V104.11.2257.2257

Published: 2004

NARROW

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

A Phase I Study Evaluating the Safety and Persistence of Allorestricted WT1-TCR Gene Modified Autologous T Cells in Patients with High-Risk Myeloid Malignancies Unsuitable for Allogeneic Stem Cell Transplantation

Predictors of Response in Patients Receiving CD34-Selected Stem Cell Infusions without Conditioning to Correct Graft Failure Following Allogeneic Stem Cell Transplantation

Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency

Successful Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation in Adults with Inherited Primary Immunodeficiency (PID)

Results of a Phase 1 Clinical Trial of Allogeneic Tumor-Primed Natural Killer Cells in AML

Positive Pre-Transplantation [18-F] FDG-PET Is Not a Barrier to Successful Allograft Outcomes in Chemosensitive Hodgkin Lymphoma

A Cell Line SYRMO Derived From AML with EVI 1 Rearrangements Following Imatinib Mesylate Therapy for Chronic Myeloid Leukaemia

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation

2-phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells

The Importance of Age, Fludarabine and Total Body Irradiation in the Incidence and Severity of Chronic Renal Failure Following Allogeneic Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only